Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Dow
QuintilesIMS
US Army
Covington
UBS
Mallinckrodt
Moodys

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOPOTECAN HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Topotecan Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00001333 Phase I Study of Intrathecal Topotecan Completed National Cancer Institute (NCI) Phase 1 The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
NCT00002395 Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) Completed SmithKline Beecham Phase 2 The purpose of this study is to see if it is safe and effective to give topotecan through a vein to treat HIV-infected patients with PML, an opportunistic (AIDS-related) infection caused by a virus that infects brain tissue and causes damage to the brain and the spinal cord. Topotecan fights HIV and the JC virus (the virus that causes PML) in laboratory experiments.
NCT00002515 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with thiotepa, carboplatin, and topotecan followed by bone marrow transplantation in treating patients who have metastatic or progressive rare cancer.
NCT00002537 Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 1 Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.
NCT00002587 Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors Completed National Cancer Institute (NCI) Phase 1 Phase I trial to study the effectiveness of paclitaxel plus topotecan in treating patients who have solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00002588 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of topotecan and etoposide in treating patients who have recurrent or refractory leukemia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Topotecan Hydrochloride

Condition Name

Condition Name for Topotecan Hydrochloride
Intervention Trials
Ovarian Cancer 69
Small Cell Lung Cancer 32
Neuroblastoma 29
Lung Cancer 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Topotecan Hydrochloride
Intervention Trials
Lung Neoplasms 78
Small Cell Lung Carcinoma 76
Ovarian Neoplasms 73
Neuroblastoma 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Topotecan Hydrochloride

Trials by Country

Trials by Country for Topotecan Hydrochloride
Location Trials
Canada 129
Germany 48
Australia 39
Italy 35
United Kingdom 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Topotecan Hydrochloride
Location Trials
California 74
New York 72
Ohio 71
Texas 68
Florida 67
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Topotecan Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Topotecan Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 46
Phase 2/Phase 3 3
[disabled in preview] 291
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Topotecan Hydrochloride
Clinical Trial Phase Trials
Completed 206
Recruiting 48
Terminated 36
[disabled in preview] 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Topotecan Hydrochloride

Sponsor Name

Sponsor Name for Topotecan Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 127
GlaxoSmithKline 57
Children's Oncology Group 14
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Topotecan Hydrochloride
Sponsor Trials
Other 340
Industry 160
NIH 132
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Colorcon
Fuji
McKinsey
Cipla
Baxter
Cerilliant
Citi
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.